Unfractionated heparin may improve near-term survival in patients admitted to the ICU with sepsis attributed to pneumonia: an observational study using the MIMIC-IV database

Shengzuo Fang, Yali Wang, Nan Wei, Yisen Feng, Wen‐Yu Su, Yiming Wang, Xiaodong JiangFrontiers in Pharmacology 2025 · DOI

TL;DR

A retrospective analysis of over 1,500 ICU patients reveals that early administration of unfractionated heparin (UFH) significantly improves 45-day survival rates for those with pneumonia-induced sepsis. The study identifies an optimal therapeutic window: a daily dose of 15,000 units (administered as 1 mL TID) for more than seven days, notably without increasing the risk of gastrointestinal bleeding.

What Problem Does This Paper Address?

Sepsis—a life-threatening organ dysfunction caused by a dysregulated host response to infection—is frequently triggered by pneumonia. A hallmark of sepsis is the dangerous interplay between systemic inflammation and runaway coagulation (clotting), which can lead to disseminated intravascular coagulation (DIC) and multi-organ failure.

While heparin is a well-known anticoagulant, its role in treating pneumonia-induced sepsis has remained controversial. Clinicians face a "Goldilocks" problem: too little might not stop microvascular thrombosis, while too much could cause fatal bleeding. Furthermore, clear guidelines on the specific dosage and duration required to actually improve survival have been lacking. This paper seeks to provide those missing parameters using real-world clinical data.

Methods

The researchers conducted a retrospective observational study using a robust statistical pipeline to mimic the rigors of a controlled trial:

  • Propensity Score Matching (PSM): To account for the fact that sicker patients might be more (or less) likely to receive heparin, the authors used PSM to create two balanced groups (588 patients each) with similar baseline characteristics, such as age, SOFA scores (organ failure severity), and comorbidities.
  • Cox Proportional Hazards Models: These were used to estimate the association between heparin use and mortality over time, adjusting for potential confounders like age and sex.
  • Collinearity Filtering: The team employed Variance Inflation Factor (VIF) analysis to exclude highly redundant variables, ensuring the statistical models remained stable and interpretable.
  • Subgroup Analysis: They broke down the data by age, chronic diseases (diabetes, COPD), and kidney injury stages to see who benefits most.

Datasets

The study utilized the MIMIC-IV (Medical Information Mart for Intensive Care-IV) database. MIMIC-IV is a massive, de-identified dataset containing clinical data from over 94,000 ICU admissions at the Beth Israel Deaconess Medical Center between 2008 and 2022. It is considered a gold standard for high-fidelity, longitudinal electronic health record (EHR) research.

Key Insights and Ideas

  • The "Sweet Spot" for Dosage: The most striking finding was that survival benefits were dose-dependent. A dose of 3 mL per day (equivalent to 15,000 units of UFH) was the "just right" amount. Interestingly, a higher dose (4.5 mL) was actually associated with an increased risk of death in some models, suggesting a narrow therapeutic index.
  • Persistence Matters: Heparin isn't a "one and done" fix. Significant survival advantages only appeared when the treatment duration exceeded seven days.
  • Beyond Thinning Blood: The authors highlight that heparin’s benefit likely stems from more than just anticoagulation. It appears to protect the endothelial glycocalyx—the delicate, gel-like layer lining our blood vessels. By preserving this barrier, heparin reduces vascular leakage and dampens the "cytokine storm" characteristic of sepsis.
  • Safety Profile: Despite the fear of bleeding associated with blood thinners, there was no statistically significant difference in gastrointestinal bleeding incidence between the heparin and non-heparin groups.

Key Results

  • Survival Boost: The 45-day survival rate was 84.4% in the heparin group compared to 79.4% in the non-heparin group.
  • Hazard Ratio: After adjusting for confounders, heparin use was associated with a 27% reduction in the risk of death (Adjusted HR: 0.73, 95% CI: 0.563–0.964).
  • Efficiency: Patients receiving heparin had significantly shorter stays in both the ICU and the hospital overall (P < 0.001).
  • Target Demographic: Subgroup analysis showed the strongest survival advantages in patients aged 18–60, those without diabetes or COPD, and those with Stage 1 Acute Kidney Injury (AKI).

Limitations and Future Work

As a retrospective study, the findings show correlation, not necessarily causation. While PSM helps, it cannot account for "unmeasured confounders"—factors not recorded in the database that might have influenced a doctor's decision to prescribe heparin.

The authors also noted:

  • Missing Biomarkers: The database lacked consistent data on specific inflammatory markers (like C-reactive protein or interleukins), which could have provided deeper insight into heparin’s anti-inflammatory mechanism.
  • Single-Center Data: Because the data comes from one hospital system, the results might not perfectly generalize to different populations or healthcare settings.

The next logical step is a multi-center, randomized controlled trial (RCT) to prospectively validate these specific dosage (15,000 units/day) and duration (>7 days) findings.

Summary updated

Abstract

Our study found that early administration of heparin, particularly in sufficient doses (Heparin Sodium 5,000 units/mL, 1 mL per dose, three times daily (TID)) for more than 7 d, was associated with reduced near-term mortality in critically ill patients with pneumonia-induced sepsis. These findings underscore the potential benefits of anticoagulant therapy in this high-risk patient population.
BibTeX
@inproceedings{fang2025unfractionated,
  author = {Shengzuo Fang and Yali Wang and Nan Wei and Yisen Feng and Wen‐Yu Su and Yiming Wang and Xiaodong Jiang},
  title = {{Unfractionated heparin may improve near-term survival in patients admitted to the ICU with sepsis attributed to pneumonia: an observational study using the MIMIC-IV database}},
  booktitle = {Frontiers in Pharmacology},
  year = {2025},
  doi = {10.3389/fphar.2025.1518716},
}
Figure